Abstract 720TiP
Background
MAPK activation by RAS and RAF mutations often drives human cancer. Targeting MAPK represents a promising route for drug development. JZP815 is a potent, selective pan-RAF kinase inhibitor that binds RAF proteins which inhibits MAPK signaling and tumor cell growth. Preclinically, JZP815 inhibited solid tumor growth in xenograft models harboring RAS/BRAF mutations, repressed a MAPK signaling marker, and generated synergy with other MAPK inhibitors.1 JZP815 also inhibited BRAF-CRAF dimer activity, representing a known resistance mechanism to BRAF V600E -specific inhibitors. The profile of JZP815 supports its progress into this FIH study.
Trial design
This phase I, open-label, multicenter study (NCT05557045) investigates the safety, dosing, and JZP815 antitumor activity in patients ≥18 years old with advanced or metastatic solid tumors harboring a documented, clinically significant alteration in MAPK. The study comprises a dose exploration phase (Part A) to characterize safety and tolerability, determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile; Part B is an expansion phase to further assess RP2D and examine antitumor activities across patient subsets based on mutation and/or tumor type, including NRAS Q61 -mutated melanoma. The starting dose is 20 mg twice daily (oral capsules). In Part A, MTD will be based on dose-limiting toxicities (DLTs) using a Bayesian optimal interval design. Patients (n≤6) may then be enrolled in pre-expansion cohorts at doses at or below MTD to obtain further safety, PK, and pharmacodynamics data before identifying RP2D. Patients will be treated until disease progression, death, unacceptable toxicity, or withdrawal. Primary endpoints include incidence and nature of DLTs (Part A), objective response rate per RECIST 1.1 (Part B), duration of response (Part B), and adverse events, changes in laboratory values or vital signs, and dose interruptions and reductions (Parts A and B). The study is enrolling with planned enrollment up to 332 patients. 1 Hauptschein R, et al. Cancer Res. 2022;82:2677. https://doi.org/10.1158/1538-7445.AM2022-2677
Clinical trial identification
NCT05557045, Release date: 27 September 2022.
Editorial acknowledgement
Editorial support was provided by Katie Groschwitz, PhD, of CMC AFFINITY, a division of IPG Health Medical Communications, with funding from Jazz Pharmaceuticals.
Legal entity responsible for the study
Jazz Pharmaceuticals.
Funding
Jazz Pharmaceuticals.
Disclosure
A. Naqash: Financial Interests, Personal, Other, Social Media Editor and Consultant: JCO Precision Oncology; Financial Interests, Institutional, Local PI: Loxo, Surface Oncology, ADC Therapeutics, IGM Biosciences, Nikang Therapeutics, Inspirna, Revolution Medicine, Jacobio, Pionyr, Jazz, NGM; Financial Interests, Institutional, Coordinating PI: EMD Serono, Aravive; Non-Financial Interests, Other, Social Media Consultant and Scientific Committee Member: ASCO; Non-Financial Interests, Other, Educational Activity: OncLive; Non-Financial Interests, Leadership Role, Scientific Committee Co-Chair: ORIEN; Non-Financial Interests, Leadership Role, Early Career Scientist Committee: SITC. J.S. Wang: Financial Interests, Personal, Invited Speaker, Previous Member of Speaker's Bureau for Tagrisso and Imfinzi, stopped in 2021: AstraZeneca; Financial Interests, Personal, Invited Speaker, Previous Member of Speaker's Bureau for Lenvima, stopped 2021: Eisai; Financial Interests, Institutional, Local PI: 7,8 Pharma, Accutar, Adagene, Artios Pharma, AstraZeneca, Blueprint, Boehringer Ingelheim, Celgene/BMS, Clovis Pharma, Cyteir, Daiichi Sankyo, Forty Seven, Genentech/Roche, Hotspot, ImmunoOnc, Janssen, Kymab, LSK BioPartners, MabSpace, Macrogenics, Moderna, Novartis, Nurix, ORIC, Olema Therapeutics, Prelude Therapeutics, Ribon Therapeutics, Syndax, Teneobio, Zymeworks; Financial Interests, Institutional, Coordinating PI: Astellas, Bayer Healthcare, BeiGene, Bicycle Therapeutics, BioNTech, BioTheryX, Biosplice, Cullinan, Erasca, GSK, H3 Biomedicine, Hutchinson MediPharma, IGM Biosciences, Immuno-Gen, Jazz Pharma, Klus Pharma, Medikine, NGM Bio, Phoenix Molecular Designs, Pionyr, PureTech Health, Pyxis, Qilu Pugent Sound, Relay Therapeutics, Revolution Medicines, Sanofi, StingThera, TopAlliance, Treadwell Therapeutics, Xencor. C.A. Perez: Financial Interests, Institutional, Local PI: Accutar Biotech, Artios Pharma, Dracen Pharmaceuticals, Elpiscience Biopharmaceuticals, Elucida Oncology, Genentech, Inc., Hyamab Inc., Jazz Pharmaceuticals, Kinnate Biopharma, Kura Oncology, Mirati Therpeutics, Relay Therapeutics, Ribbon Therapeutics, Seagen Inc., Tallac Therapeutics, Xilio Therapeutics, Zhuhai Yufan Biotechnologies Co. J.T. Henry: Financial Interests, Personal, Full or part-time Employment, Associate Director/Oncologist: Sarah Cannon Research Institute; Financial Interests, Personal, Stocks/Shares: HCA; Financial Interests, Institutional, Local PI: Abbiscko Therapeutics, ABl bio, Accutar biotech ADC therapeutics, Agenus, Aileron Therapeutics, Amgen Inc., Artios, Astrazenaca, Bicycle therapeutics, BioAlta, BioInvent pharma, Biosplice therapeutics, Black diamond therapeutics, Boehringer, Ingelheim, Cyteir, Daiichi Sankyo, Eli Lilly, Epizyme, Erasca, Exelixis, FujiFilm, GSK, Hutchison MediPharma, ICON plc, IGM Biosciences, Immunogen, Jacobio pharmaceuticals, Jounce pharma, Jubilant therapeutics, Loxo Oncology, Merck& CO, Metabomed, Molecular templates, Navire Pharma, Nikang pharmaceuticals, Oncorus, Prelude therapeutics, Poseida, PureTech, Pyramid, Rascal Therapeutics, Regeneron, Relay Therapeutics, Rgenix Inc., Ribon therapeutics, Sapience, Sarah Cannon Development Innovations, Sarah Cannon Research Institute, Seagen, Simcha Therapeutics, Siranomics, Stingthera, Synthorx Inc., Takeda pharmaceuticals, Tallac therapeutics, Tarveda, Teneothree, Tesaro, Turning point pharma, Xencor, Immunitas, Mirati, Pyxis, Jazz Pharmaceuticals, Nikang, Bayer, Kineta, NGM Bio, Roche, Tarus Therapeutics. B. Bashir: Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Institutional, Other, Clinical Trial Research: Eisai, Amgen, Artios, Bicycle Therapeutics, Boehringer Ingelheim, Gritstone Bio, Ikena Oncology, Jazz Pharmaceuticals, KAHR Medical, Lyell immunopharma, Merck, Pionyr Immunopharma, RASCAL Therapeutics, Syros Pharmaceuticals, Tarveda Therapeutics. A. Panneerselvam, S. Markova, R.S. Cheung: Financial Interests, Personal, Full or part-time Employment: Jazz Pharmaceuticals; Financial Interests, Personal, Stocks or ownership: Jazz Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17